Yu-E Huang
Overview
Explore the profile of Yu-E Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cao X, Zhou X, Hou F, Huang Y, Yuan M, Long M, et al.
Nucleic Acids Res
. 2023 Nov;
52(D1):D1393-D1399.
PMID: 37953323
Drug resistance is a major barrier in cancer treatment and anticancer drug development. Growing evidence indicates that non-coding RNAs (ncRNAs), especially microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs...
2.
Li C, Fan R, Li D, Zhou W, Huang Y, Wang B
Zhongguo Ying Yong Sheng Li Xue Za Zhi
. 2023 Jun;
38(6):617-621.
PMID: 37308405
To investigate the protective effects of erythropoietin derived peptide, also known as spiral B surface peptide (HBSP), on kidney and aggregated proteins (Agrin) levels in acute skeletal muscle strain rats....
3.
DRdriver: identifying drug resistance driver genes using individual-specific gene regulatory network
Huang Y, Zhou S, Liu H, Zhou X, Yuan M, Hou F, et al.
Brief Bioinform
. 2023 Mar;
24(2).
PMID: 36869849
Drug resistance is one of principal limiting factors for cancer treatment. Several mechanisms, especially mutation, have been validated to implicate in drug resistance. In addition, drug resistance is heterogeneous, which...
4.
Lei W, Yuan M, Long M, Zhang T, Huang Y, Liu H, et al.
Genes (Basel)
. 2023 Feb;
14(2).
PMID: 36833194
Heterogeneity exists inter- and intratumorally, which might lead to different drug responses. Therefore, it is extremely important to clarify the drug response at single-cell resolution. Here, we propose a precise...
5.
Chen S, Zhou S, Huang Y, Yuan M, Lei W, Chen J, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499343
Pancreatic ductal adenocarcinoma (PDAC) is characterized by intra-tumoral heterogeneity, and patients are always diagnosed after metastasis. Thus, finding out how to effectively estimate metastatic risk underlying PDAC is necessary. In...
6.
Liu H, Yuan M, Mitra R, Zhou X, Long M, Lei W, et al.
Genome Med
. 2022 Oct;
14(1):118.
PMID: 36229842
Background: Pathway enrichment analysis (PEA) is a common method for exploring functions of hundreds of genes and identifying disease-risk pathways. Moreover, different pathways exert their functions through crosstalk. However, existing...
7.
Hou F, Zhou X, Zhou S, Liu H, Huang Y, Yuan M, et al.
iScience
. 2022 Jun;
25(6):104493.
PMID: 35712082
Long-term isolation is one of the risk factors that astronauts will encounter in spaceflight. At present, few researches have explored DNA methylation dynamics during long-term isolation. In this study, using...
8.
Zhou S, Huang Y, Liu H, Zhou X, Yuan M, Hou F, et al.
Mol Ther Nucleic Acids
. 2021 Feb;
23:682-690.
PMID: 33575114
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with high intratumoral heterogeneity. Recent studies revealed that TNBC patients might comprise cells with distinct molecular subtypes. In addition, gene...
9.
Yuan M, Liu H, Zhou S, Zhou X, Huang Y, Hou F, et al.
Int J Mol Sci
. 2020 Oct;
21(20).
PMID: 33066530
Previous studies have demonstrated that microgravity could lead to health risks. The investigation of the molecular mechanisms from the aspect of systems biology has not been performed yet. Here, we...
10.
Liu H, Zhou X, Yuan M, Zhou S, Huang Y, Hou F, et al.
J Mol Biol
. 2020 Feb;
432(11):3364-3368.
PMID: 32105730
Noncoding RNAs (ncRNAs), such as lncRNAs, circRNAs and pri-miRNAs, play important roles in physiological and pathological processes. Recently, it was demonstrated that they could encode proteins or peptides. However, relevant...